A recent study reveals that patients who come off new GLP-1 drugs like Wegovy and Mounjaro may regain reduced body mass far faster than those who end conventional diet and exercise regimens.
Research printed in a leading health publication demonstrates that while overweight people frequently drop a large proportion of their total mass while on the medication, the mass is regained at an estimated rate of 0.8 kg per month after stopping.
"People purchasing such treatments need to be informed of the risk of quick weight regain when the medication is stopped," stated expert Dr. Susan Jebb.
That rate of regain means a reversion to original mass within about one and a half years.
Comparing Approaches
The study, which looked at dozens of trials involving over 9,000 of patients, contrasted the results of GLP-1 agonists with older methods.
Researchers note that people who shed pounds through diet and exercise generally see a more gradual weight regain—perhaps 100 grams monthly—once they finish.
Understanding the Fast Regain
Doctors suggest the mechanism of the injections accounts for the heightened regain.
The injections mimic a body's own chemical called glucagon-like peptide-1, which helps regulate hunger.
"Long-term administration of the hormone levels far above than normal may cause the body to generate a reduced amount of its own natural GLP-1, and may also diminish responsiveness to its effects," said Dr. Adam Collins, a dietetics researcher.
"Discontinuation of this GLP-1 'fix' results in appetite is uncontrolled, making excessive eating far more likely."
A Lifelong Issue?
The NHS suggest the injections for individuals with weight-linked health risks, alongside prescribed lifestyle changes.
Professionals contend that, given the likelihood of relapse, the therapy is often ongoing.
This perspective is echoed by pharmaceutical companies, who say that the findings "underscore the chronic nature of obesity," comparing it to managing diseases like diabetes.
Patient Experiences
Individuals who have stopped the jabs describe a intense resurgence of hunger.
"It was like a trigger that goes on and I was suddenly starving," described a patient.
This challenge is exacerbated if users have not adopted permanent lifestyle or habit changes during therapy.
Significant Interest
Survey data suggest that a significant number of people in the UK have used these injections in the past year, with interest remaining high.
- Use is higher among women than males.
- The 40s and 50s age group shows the greatest level of interest.
- Many access the medications through private healthcare rather than the NHS.
Ultimately, clinicians caution that while these medications are powerful tools for weight loss, they are not a magic fix and long-term success likely depends on ongoing behavioural management.
